IPAB quashes revocation of Novartis patent for anti-cancer drug Ceritinib




Natco filed a post-grant opposition against the patent on September 26, 2017, on grounds of obviousness and lack of inventive step.



Source link

Leave a Comment

Your email address will not be published.